Rare Disease

FDA Halts Regenxbio Hunter Syndrome Gene Therapy Amid Safety Signal

The FDA has placed a second clinical hold this year on Regenxbio's Hunter syndrome gene therapy after investigators detected spinal masses in five treated patients. The recurrence of a safety signal in a program targeting a rare, life-limiting lysosomal storage disorder raises fresh questions about the long-term monitoring burden for one-time genetic medicines. Stakeholders should watch how the agency and sponsor characterize the masses, whether they are treatment-related, and what it means for the broader AAV gene therapy field. Families awaiting durable options for Hunter syndrome now face renewed uncertainty.

RxWare Perspective

Repeated holds underscore that patient access for gene therapies extends well beyond approval—longitudinal safety surveillance and transparent family communication must be engineered into access programs from day one.

Pharma Trends

4 stories

Pipeline

Moderna–Merck Cancer Vaccine Clears Phase 3; Ultragenyx Lands GSDIa Nod

Moderna and Merck's personalized mRNA melanoma vaccine met two Phase 3 endpoints, while the FDA cleared the first-ever treatment for glycogen storage disease type Ia (GSDIa) from Ultragenyx. The dual milestones mark advances in both personalized oncology and ultra-rare metabolic disease.

RxWare View: Personalized and ultra-rare therapies raise the bar for patient identification and hub coordination—clinical wins mean little without access execution.

PharmaVoice · 18h ago

Market

Cellares to Lay Off 100 as Cell Therapy Manufacturing Contract Ends

Cell therapy manufacturing specialist Cellares will cut 100 employees after a large pharmaceutical customer terminated a contract. The restructuring highlights ongoing volatility in the cell and gene therapy supply chain.

RxWare View: Manufacturing disruptions are patient access disruptions—supply chain resilience belongs on every specialty access program's risk map.

BioPharma Dive · 18h ago

Pipeline

Tyra Biosciences Nears First Phase 2 Test of One-Drug, Three-Indication Bet

Clinical-stage biotech Tyra Biosciences is approaching its first Phase 2 readout for an FGFR3-targeted candidate spanning cancer and achondroplasia. The multi-indication strategy carries blockbuster potential across both oncology and rare skeletal disease.

RxWare View: Multi-indication assets demand modular access architecture—one program cannot serve oncology and rare pediatric populations with a single playbook.

PharmaVoice · 1d ago

Market

Biopharma Hiring Rebounds as Q2 Layoffs Fall 59%, Postings Climb 15%

After several turbulent years of workforce cuts, 59% fewer pharma companies reduced staff in Q2 2026 while job postings rose 15%. The data suggests a stabilizing labor market across the biopharma sector.

RxWare View: A recovering talent market is welcome, but specialty access expertise remains scarce—technology-enabled workflows help teams do more with lean staffing.

Drug Discovery Trends · 1d ago

Regulatory Watch

2 updates

FDA

FDA Finalizes PDUFA Meeting Guidance, Expands Written Responses

The FDA has finalized guidance governing sponsor meetings under the Prescription Drug User Fee Act, expanding the use of written responses. The change updates draft guidance first issued in September 2023.

RxWare View: Faster, clearer regulatory interactions ultimately accelerate the path to patient access—especially for rare disease programs racing against progressive disease.

Drug Discovery Trends · 1d ago

CMS

Medicaid Obesity Drug Coverage Falls Short of Federal Pledge

A pledge to broaden access to costly weight-loss drugs for low-income Americans through Medicaid is not materializing as promised. State-level coverage decisions continue to limit availability of GLP-1 therapies.

RxWare View: State Medicaid fragmentation makes geographic access mapping essential—patients' options too often depend on their zip code, not their diagnosis.

STAT News · 1d ago

RxWare Perspective

Gene Therapy Post-Approval Surveillance

The repeated safety holds in AAV gene therapy programs highlight that the access journey does not end at infusion. Durable, one-time therapies require years of structured longitudinal monitoring, and access programs must build in mechanisms for adverse event tracking, family communication, and continuity of specialist follow-up.

Manufacturing as an Access Layer

Cell and gene therapy supply chains remain fragile, and manufacturing disruptions can silently become patient access failures. Forward-looking specialty programs are treating supply resilience and manufacturing transparency as core components of access strategy, not isolated operational concerns.

State-Level Coverage Fragmentation

As high-cost therapies proliferate, the gap between federal coverage aspirations and state budget realities is widening. Specialty pharma stakeholders should invest in granular, geography-aware access intelligence to help patients navigate a patchwork of payer decisions that too often override clinical need.

Upcoming in Specialty Pharma

OCT 19

Conference

AMCP Nexus 2026

October 19, 2026 · Las Vegas, NV

Premier managed care pharmacy event addressing formulary, reimbursement, and specialty access strategy.

Visit website ↗

NOV 17

Congress

World Orphan Drug Congress USA 2026

November 17, 2026 · Boston, MA

Leading gathering focused on rare disease development, market access, and patient advocacy.

Visit website ↗

APR 26

Summit

Asembia AXS27 Specialty Pharmacy Summit

April 26, 2027 · Las Vegas, NV

The industry's largest specialty pharmacy event covering patient access, hub services, and reimbursement.

Visit website ↗

What is MCP?